Repatha Copay Card & Savings Guide: 2026
Repatha (evolocumab) is a PCSK9 inhibitor — the injectable cholesterol drug for people whose LDL won’t come down enough on statins, or who can’t tolerate statins at all. List price runs around $500+ a month, but almost nobody paying attention pays that: between a solid copay card, an actual free-drug foundation, and Medicare’s redesigned benefit, the real Repatha cost question is which program you belong in. Here’s the sorting.
What you’ll pay with the Repatha copay card
With the Repatha coupon — the official Amgen co-pay card — eligible commercially insured patients pay as little as $25 for a 1-month supply or $50 for a 3-month supply, — the official advertised minimums. [1][2] Monthly and annual maximum benefits apply, and Amgen’s published terms (repatha.com/copaytcs) set the specifics — which is why the smartest move in this program is the one below.
The usual mechanics apply: the card pays down your copay up to its monthly and annual maximums, so high-coinsurance tiers and early-year deductibles can leave you a balance above the advertised floor. Amgen is unusually transparent about this — SupportPlus representatives (1-844-REPATHA) will walk your specific plan’s math and tell you whether you’re likely to hit the caps. Use them; that call is the difference between a budget and a surprise.
One genuinely distinctive term: plans bought through the healthcare exchanges qualify. Most manufacturer cards treat marketplace plans inconsistently; Amgen’s terms include them explicitly. [2] Medicare, Medicaid, TRICARE, and other government coverage remain excluded, as with every card in this series.
Enrollment: at repatha.com or through the SupportPlus line; the card applies at the pharmacy (or with your specialty pharmacy, which handles most Repatha fills). Re-enroll each calendar year.
Repatha on Medicare: better than the old horror stories
The copay card is off-limits to Medicare patients — but two structural changes make it worth re-checking your actual number rather than assuming the worst:
- The Part D out-of-pocket cap limits annual drug spending plan-wide, which defuses the old “PCSK9s eat your whole donut hole” problem.
- The Medicare Prescription Payment Plan spreads that capped cost evenly across the year — ask your plan to enable it rather than front-loading January.
Call your Part D plan for Repatha’s current tier and your projected annual cost; for many patients the real answer now lands in manageable territory. If it still doesn’t, the foundation below considers underinsured Medicare patients.
Repatha patient assistance: Amgen Safety Net Foundation
For the uninsured and underinsured, the Amgen Safety Net Foundation provides Repatha at no cost to patients who qualify by income. [3] Income limits are FPL-based and vary by Amgen product (set higher for Alaska and Hawaii); the fastest check is the pre-screen at 1-800-932-3060. The application follows the standard patient-assistance shape — income documentation, prescriber section, a few weeks’ processing, annual renewal — and the same SupportPlus line screens you for the right program, which is the sensible first call whatever your insurance situation. Application mechanics in detail: our patient assistance guide.
Winning the prior authorization
Repatha’s coverage hurdle is predictable: PCSK9 inhibitors are expensive, so nearly every plan requires a prior authorization demonstrating the statin story. What wins it:
- Statin intolerance, documented — muscle pain (myalgia) that resolved off-statin and returned on rechallenge is the classic pattern; the chart needs to name the statins tried and what happened.
- Above-goal LDL on maximum tolerated therapy — recent labs showing LDL still above target despite a maximally dosed statin (with or without ezetimibe) is the other winning fact pattern.
- Established cardiovascular disease or familial hypercholesterolemia — the indications where guidelines most strongly support PCSK9 therapy; make sure the diagnosis codes are on the request.
Denials are appealable and frequently overturned when the documentation above actually makes it into the letter. If your plan prefers the competing PCSK9 (Praluent) or the newer siRNA option (Leqvio, administered in-office and billed medically — sometimes an insurance workaround worth asking about), that’s a legitimate clinical conversation, not just a coverage one.
The rest of the toolkit
- 90-day fills at $50 through the card are the best per-month value for stable patients.
- HSA/FSA funds apply; keep receipts.
- Don’t stretch doses. Repatha’s LDL effect fades within weeks of stopping; skipped doses quietly surrender the protection you’re paying for. If cost is forcing that choice, call SupportPlus first — sorting patients into the right program is literally the desk’s job.
Frequently Asked Questions
How much is Repatha with the copay card?
Eligible commercially insured patients pay as little as $25 for a 1-month supply or $50 for 3 months, subject to monthly and annual maximum benefits — Amgen SupportPlus (1-844-REPATHA) will confirm your plan’s exact numbers.
Does the Repatha card work with marketplace (exchange) plans?
Yes — unusually, Amgen’s card explicitly includes commercial plans bought through state and federal healthcare exchanges. Government programs like Medicare and Medicaid remain excluded.
What does Repatha cost on Medicare?
The copay card is off-limits, but Part D’s redesigned benefit caps annual out-of-pocket drug costs, and the Medicare Prescription Payment Plan can spread costs across the year. Check your plan’s Repatha tier — many patients’ real number is far below the old horror stories.
Is there free Repatha for low-income patients?
Yes — the Amgen Safety Net Foundation provides Repatha at no cost to qualifying uninsured or underinsured patients based on income. Call Amgen SupportPlus at 1-844-REPATHA to be screened for the right program.
Why does insurance make Repatha so hard to get approved?
PCSK9 inhibitors are expensive, so plans require prior authorization showing statins were tried and failed, weren’t tolerated, or didn’t get LDL low enough. Documented statin intolerance or an LDL still above goal on maximum therapy is exactly what wins the approval.
Sources
This guide covers cost and access, not medical advice — talk to your prescriber before changing how you take Repatha. Program terms, prices, and eligibility change without notice; confirm current details with the official program (linked in the sources above) before relying on them. We’re an independent publisher, not affiliated with or endorsed by Amgen — see our full medical disclaimer.